Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Numinus Wellness Inc
NUMIF
Primary Symbol:
T.NUMI
Healthcare
Numinus Wellness Inc. is a mental health care company. The Company focuses on advancing traditional and behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies. Its segments include Clinical research operations, Practitioner Training, Clinic network, and Corporate. Clinical research operations segment is focused on licensed psychedelic research and...
provides clinical research management services to academic institutions and biotechnology companies. Practitioner Training segment is engaged in education and training for research and drug development organizations to support clinical trials and commercialization efforts. Clinic network segment includes wellness clinics, which is engaged in providing clinical services from psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management. Corporate segment includes finance, marketing, information technology, legal, and human resources.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
TSX:NUMI - Post Discussion
Numinus Wellness Inc
> Numinus approved for pioneering MDMA-based clinical trial
New Post
View:
Discussion
List
(503)
•••
TrevorAbes
X
View Profile
View Bullboard History
Post by
TrevorAbes
on May 30, 2024 11:50am
Numinus approved for pioneering MDMA-based clinical trial
https://stockhouse.com/news/the-market-online-news/2024/05/30/numinus-approved-for-pioneering-mdma-based-clinical-trial
(368)
•••
Traderstock101
X
View Profile
View Bullboard History
Comment by
Traderstock101
on Jul 04, 2024 12:53pm
This post has been removed in accordance with Community Policy
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
New Gold and Copper Hotspot Identified – What’s Next for This Serbian Project?
Major Funding Secured! Company Closes First Round of Private Placement
This $10M Deal Could Reshape the Future of Global Creator Platforms